Melanoma Posts on Medivizor
Navigation Menu

Melanoma Posts on Medivizor

Investigating the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma.

Investigating the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma.

Posted by on May 8, 2022 in Melanoma | 0 comments

In a nutshell This study investigated the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma. The data showed that patients who underwent less frequent imaging (12-monthly) had better outcomes than those who underwent more frequent imaging (3- to 4-monthly). Some background Melanoma is a...

Read More

Vacations for Adult Cancer Patients: Update

Vacations for Adult Cancer Patients: Update

Posted by on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 0 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update.  Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Read More

Evaluating the risk of lung inflammation associated with immunotherapy in advanced melanoma.

Evaluating the risk of lung inflammation associated with immunotherapy in advanced melanoma.

Posted by on Dec 31, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the risk of pneumonitis (inflammation of the lung tissue) associated with immune checkpoint inhibitors (ICIs) for the treatment of patients with advanced melanoma. The data showed that ICIs were associated with a higher risk of pneumonitis compared with conventional chemotherapy in patients with advanced melanoma. Some...

Read More

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Posted by on Dec 19, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) in combination with palliative (treatment to relieve pain) radiotherapy (pRT) for the treatment of patients with advanced melanoma. The data showed that the addition of pRT to ICIs is effective and safe in these patients. Some background Melanoma is...

Read More

Evaluating the effectiveness and safety of sequential administration of high dose aldesleukin and ipilimumab in patients with metastatic melanoma.

Evaluating the effectiveness and safety of sequential administration of high dose aldesleukin and ipilimumab in patients with metastatic melanoma.

Posted by on Dec 5, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of sequential administration of high dose aldesleukin (Interleukin-2; Proleukin) and ipilimumab (Yervoy) in patients with metastatic melanoma. The data showed that high dose aldesleukin and ipilimumab were effective and safe when administered sequentially in these patients. Some background...

Read More

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Posted by on Nov 27, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness of talimogene laherparepvec (Imlygic; T-VEC) after failure of immunotherapy for the treatment of patients with unresectable metastatic melanoma. The data showed that T-VEC after the failure of immunotherapy is safe and effective in these patients. Some background Melanoma is an aggressive type of...

Read More

Evaluating the effectiveness and safety of T-VEC plus surgery for the treatment of patients with resectable advanced stage melanoma.

Evaluating the effectiveness and safety of T-VEC plus surgery for the treatment of patients with resectable advanced stage melanoma.

Posted by on Nov 14, 2021 in Melanoma | 0 comments

In a nutshell This study compared the effectiveness and safety of talimogene laherparepvec (Imlygic; T-VEC) plus surgery versus surgery alone for the treatment of patients with resectable advanced stage (III or IV) melanoma. The data showed that T-VEC plus surgery was safe and effective for these patients. Some background Melanoma is an aggressive...

Read More

Evaluating the outcomes of current therapies after surgery for patients with stage III melanoma who did not undergo complete lymph node dissection.

Evaluating the outcomes of current therapies after surgery for patients with stage III melanoma who did not undergo complete lymph node dissection.

Posted by on Oct 31, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the outcomes of immune and molecular targeted therapies after surgery for patients with stage III melanoma who did not undergo complete lymph node dissection. The data showed that the immune and targeted therapies after surgery were associated with increased survival without metastasis among these patients. Some...

Read More

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Posted by on Oct 31, 2021 in Melanoma | 0 comments

In a nutshell This study investigated the optimal doses of hypofractionated stereotactic radiation therapy (HSRT) for patients with brain metastases (BM). The data showed that a HSRT dose of 30 Gy or higher delivered in 5 daily fractions was safe and effective in these patients. Some background Stereotactic radiosurgery (SRS) is commonly...

Read More

Does tebentafusp provide survival benefit in patients with advanced uveal melanoma?

Does tebentafusp provide survival benefit in patients with advanced uveal melanoma?

Posted by on Oct 17, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to investigate the safety and effectiveness of immunotherapy drug tebentafusp in previously untreated advanced uveal melanoma. The study showed that tebentafusp is effective and improved the overall survival in patients with uveal melanoma. Some background Melanoma is an aggressive kind of skin cancer. Uveal melanoma...

Read More

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Melanoma | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the...

Read More

Does early use of high-dose glucocorticoids affect survival in patients with advanced melanoma treated with anti-PD-1 therapy?

Does early use of high-dose glucocorticoids affect survival in patients with advanced melanoma treated with anti-PD-1 therapy?

Posted by on Sep 17, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the use of high-dose glucocorticoids (GCs) and their impact on the survival outcomes during anti-PD-1 therapy for the treatment of patients with advanced melanoma. The data showed that early high-dose GC use was associated with poorer outcomes after the onset of immune-related side effects. Some background...

Read More